ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Clinical trials for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE explained in plain language.
Never miss a new study
Get alerted when new ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE trials appear
Sign up with your email to follow new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise against aggressive t-cell lymphoma
Disease control OngoingThis study tested a combination of a targeted drug (brentuximab vedotin) and chemotherapy in 48 people with a rare type of blood cancer called CD30-positive peripheral T-cell lymphoma. The goal was to see how well the treatment shrinks tumors and what side effects occur. Particip…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Virus-Immunotherapy combo targets tough skin cancers
Disease control OngoingThis study tests a two-step treatment for people with rare skin cancers or certain lymphomas that haven't improved with standard care. First, patients receive a virus-based drug (talimogene laherparepvec) injected into tumors to help the immune system recognize and attack cancer …
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:47 UTC